Neurocrine Biosciences

This study tested a drug called NBI-827104 in 24 children with a rare epilepsy that causes constant brain spikes during sleep. The drug is a calcium channel blocker given daily for 13 weeks. The main goal was to see if it reduces abnormal brain activity measured by EEG.

This phase 2 trial tested an experimental drug called NBI-1070770 in 73 adults with major depressive disorder. Participants took the drug or a placebo for 5 days to see if it could quickly improve depression symptoms. The study is already completed, and results will show whether …

This Phase 3 study tested the long-term safety of valbenazine in 154 people with Huntington disease who have chorea (uncontrolled movements). Participants either continued from a previous study or joined new. The goal was to see if valbenazine is safe and helps control chorea ove…

This study tested a drug called valbenazine to see if it can reduce jerky, uncontrolled movements (chorea) in people with cerebral palsy. The trial included 86 children and adults whose medical condition was stable. Participants received either valbenazine or a placebo for 14 wee…

This study tested whether adding valbenazine to standard antipsychotic medication helps reduce schizophrenia symptoms in adults who did not respond well to treatment alone. Over 400 participants took either valbenazine or a placebo for 10 weeks. Researchers measured changes in sy…

This completed Phase 4 study tested valbenazine in 59 adults with tardive dyskinesia (involuntary muscle movements) caused by psychiatric medications. Participants had schizophrenia, bipolar disorder, or major depression. Over 24 weeks, researchers measured changes in quality of …